Stifel raised the firm’s price target on OrthoPediatrics to $34 from $32 and keeps a Buy rating on the shares. The firm notes that OrthoPediatrics delivered a largely as-expected quarter, with Q4 in-line with the preannouncement and reiterated 2024 guide. Still, multiple new product launches, the Boston O&P acquisition integration, and improving macro environment seem to argue positively for a favorable KIDS 2024 setup, potential for continued double-digit top-line growth, and opportunity for upside as the year unfolds, Stifel says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results
- OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis
- KIDS Earnings this Week: How Will it Perform?
- OrthoPediatrics participates in a conference call with BTIG
- OrthoPediatrics Corp. Named One of the 2024 Best Places to Work in Indiana